Barriers to cardiovascular disease risk scoring and primary prevention in Europe

QJM: An International Journal of Medicine

Volumn 103, Issue 10, 2010, Pages 727-739

  Hobbs, F D R ^a   Jukema, J W ^b   Da silva, P M ^c   McCormack, T ^d   Catapano, A L ^e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL DE SANTA MARTA   (Portugal)

^d Spring Vale Medical Centre   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

AWARENESS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DIABETES MELLITUS; DIETARY INTAKE; DISEASE COURSE; ELECTROCARDIOGRAM; EUROPE; HEALTH SURVEY; HEART INFARCTION; HEART RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERPERSONAL COMMUNICATION; LIFESTYLE MODIFICATION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 77957276698     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq122     Document Type: Review

References (89)

1. World Health Organization. The global burden of disease 2004 update. [www.who.int/healthinfo/global_burden_disease/2004_report_update] Accessed 6 November 2009.
2. Multiple Risk Factor Intervention Trial Research Group. Risk factor changes and mortality results. JAMA 1982; 248:1465-77.
3. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987; 257:2176-80.
4. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274:131-6.
5. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-74.
6. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290:891-7.
7. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904.
8. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
9. The Health Benefits of Smoking Cessation: a Report of the Surgeon General. Rockville, MD, US Dept of Health and Human Services, 1990.
10. Hu FB, Rimm EB, Stampfer MJ, Ascherio A, Spiegelman D, Willett WC. Prospective study of major dietary patterns and risk of coronary heart disease in men. Am J Clin Nutr 2000; 72:912-21.
11. Kant AK, Schatzkin A, Graubard BI, Schairer C. A prospective study of diet quality and mortality in women. JAMA 2000; 283:2109-15.
12. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343:16-22.
13. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a longacting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-72.
14. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
15. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-51.
16. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289:2073-82.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-97.
18. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-92.
19. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and betablockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-65.
20. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-6.
21. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-6.
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002; 360:7-22.
23. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-30.
24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007.
25. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
26. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-504.
27. Wood DA. Clinical reality of coronary prevention in Europe: a comparison of EUROPASPIRE I, II, and III surveys. Paper presented at The 29th Annual Congress of the European Society of Cardiology. Vienna, Austria. 1-5 September, 2007.
28. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 2008; 156:112-9.
29. Graham I. Cardiovascular disease prevention in clinical practice. Cardiovascular Medicine; Compendium of Abridged ESC Guidelines 2008. ESC committee for practice guidelines. London, UK, Wolters Kluwer Health, Lippincott Williams & Wilkins, 3-13.
30. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115:114-26.
31. Laker MF. Cardiovascular disease prevention: the new Joint British Societies' guidelines. Ann Clin Biochem 2006; 43:335-9.
32. Pasternak RC. Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults. Cardiol Clin 2003; 21:393-8.
33. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106:388-91.
34. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-8.
35. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
36. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. Br Med J 2007; 335:136.
37. Beswick A, Brindle P. Risk scoring in the assessment of cardiovascular risk. Curr Opin Lipidol 2006; 17:375-86.
38. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl 5):v1-52.
39. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 2):S1-113.
40. Rose G. Strategies of prevention: the individual and the population. In: Marmot M, Elliott P, eds, Coronary Heart Disease Epidemiology: From Aetiology to Public Health. 2nd edn. Oxford: Oxford University Press, 2005:631-41.
41. Leong T, McGorrian C, Graham IM. Cardiovascular epidemiology: background and principles of cardiovascular disease prevention. In: Graham IM, D'Agostino RB, eds, Therapeutic Strategies in Cardiovascular Risk. Oxford, Clinical Publishing, 2008:5-16.
42. Kaplan RM, Ong M. Rationale and public health implications of changing CHD risk factor definitions. Annu Rev Public Health 2007; 28:321-44.
43. Conroy RM. From epidemiological risk to clinical practice by way of statistics a personal view. In: Graham IM, D'Agostino RB, eds, Therapeutic Strategies in Cardiovascular Risk. Oxford: Clinical Publishing, 2008:17-40.
44. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-riskfactor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100:1481-92.
45. Rouff GE. Evidence-based cardiovascular disease prevention: challenges to assessing risk on office practice. Consultant 2005; 45:1-11.
46. Rodriguez-Artalejo F, Banegas JR. Cardiovascular risk in clinical decision making. Curr Hypertens Rep 2007; 9:339-41.
47. Eaton CB, Galliher JM, McBride PE, Bonham AJ, Kappus JA, Hickner J. Family physician's knowledge, beliefs, and selfreported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med 2006; 19:46-53.
48. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-421.
49. Oriol-Zerbe C, Abholz HH. Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators. Eur J Gen Pract 2007; 13:27-34.
50. Graham IM, Stewart M, Hertog MG. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil 2006; 13:839-45.
51. Persson M, Carlberg B, Tavelin B, Lindholm LH. Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy. J Hypertens 2004; 22:65-71.
52. World Health Organization. International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-83.
53. Scholte op Reimer WJ, Moons P, De Geest S, Fridlund B, Heikkila J, Jaarsma T, et al. Basel 2005 Nurses Cohort. Cardiovascular risk estimation by professionally active cardiovascular nurses: results from the Basel 2005 Nurses Cohort. Eur J Cardiovasc Nurs 2006; 5:258-63.
54. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111:499-510.
55. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105:310-5.
56. Baena-Diez JM, Grau M, Sanchez-Perez R, Altes-Vaques E, Salas-Gaetjens LH, Hernandez-Ibanez MR. The REGICORcalibrated function provides a better classification of highrisk patients on statin treatment in the Spanish population than the Framingham or SCORE classifications. Rev Esp Cardiol 2009; 62:1134-40.
57. Chen L, Tonkin AM, Moon L, Mitchell P, Dobson A, Giles G, et al. Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart. Eur J Cardiovasc Prev Rehabil 2009; 16:562-70.
58. Chow CK, Joshi R, Celermajer DS, Patel A, Neal BC. Recalibration of a Framingham risk equation for a rural population in India. J Epidemiol Community Health 2009; 63:379-85.
59. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. Br Med J 2009; 339:b2584.
60. Gonzalez-Diego P, Moreno-Iribas C, Guembe MJ, Vines JJ, Vila J. Adaptation of the Framingham-Wilson coronary risk equation for the population of Navarra (RICORNA). Rev Esp Cardiol 2009; 62:875-85.
61. Woodward M, Brindle P, Tunstall-Pedoe H; SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007; 93:172-6.
62. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006; 92:1752-9.
63. Brindle P, May M, Gill P, Cappuccio F, D'Agostino R Sr, Fischbacher C, et al. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart 2006; 92:1595-602.
64. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. Br Med J 2002; 325:1271.
65. de Visser CL, Bilo HJ, Thomsen TF, Groenier KH, Meyboomde Jong B. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med 2003; 253:553-62.
66. Persson M, Carlberg B, Weinehall L, Nilsson L, Stegmayr B, Lindholm LH. Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. J Hypertens 2003; 21:1089-95.
67. Tunstall-Pedoe H, Woodward M. By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart 2006; 92:307-10.
68. Simmons RK, Coleman RL, Price HC, Holman RR, Khaw KT, Wareham NJ, et al. Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPICNorfolk Cohort. Diabetes Care 2009; 32:708-13.
69. Torley D, Zwar N, Comino EJ, Harris M. GPs' views of absolute cardiovascular risk and its role in primary prevention. Aust Fam Physician 2005; 34:503-4, 7.
70. Palmieri L, Panico S, Vanuzzo D, Ferrario M, Pilotto L, Sega R, et al. for the Research Group of the Project HEART. Evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score [in Italian]. Ann Ist Super Sanita 2004; 40:393-9.
71. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. Br Med J 2008; 336:1475-82.
72. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113:791-8.
73. Muchiteni T, Borden WB. Improving risk factor modification: a global approach. Curr Cardiol Rep 2009; 11:476-83.
74. Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004; 94:20-4.
75. Marshall T. The effect of blood pressure and cholesterol variability on the precision of Framingham cardiovascular risk estimation: a simulation study. J Hum Hypertens. [Epub ahead of print 7 January 2010; doi: 10.1038/jhh.2009.114].
76. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611-9.
77. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-53.
78. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation 2009; 119:3078-84.
79. Broedl UC, Geiss HC, Parhofer KG. Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy. J Gen Intern Med 2003; 18:190-5.
80. Eichler K, Zoller M, Tschudi P, Steurer J. Barriers to apply cardiovascular prediction rules in primary care: a postal survey. BMC Fam Pract 2007; 8:1.
81. van Steenkiste B, van der Weijden T, Stoffers HE, Grol R. Barriers to implementing cardiovascular risk tables in routine general practice. Scand J Prim Health Care 2004; 22:32-7.
82. van Steenkiste B, van der Weijden T, Timmermans D, Vaes J, Stoffers J, Grol R. Patients' ideas, fears and expectations of their coronary risk: barriers for primary prevention. Patient Educ Couns 2004; 55:301-7.
83. Hartz I, Njolstad I, Eggen AE. Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromso study 2001. Eur Heart J 2005; 26: 2673-80.
84. Marshall T. Estimating the value of information in strategies for identifying patients at high risk of cardiovascular disease. Inform Prim Care 2006; 14: 85-92.
85. Erhardt LR. Barriers to effective implementation of guideline recommendations. Am J Med 2005; 118 (Suppl 12A):36-41.
86. Quality and outcomes framework guidance: updated August 2004. [www.dh.gov.uk/en/Healthcare/Primarycare/Primary carecontracting/QOF] Accessed 13 November 2009.
87. Putting prevention first. Vascular checks: risk assessment and management. Vascular programme, Department of Health, National Health Service, London, UK. [www.dh.gov.uk/publications] Accessed 13 November 2009.
88. Sinclair G, Kerr A. The Bold Promise Project: a system change in primary care to support cardiovascular risk screening. N Z Med J 2006; 119:U2312.
89. Wells S, Furness S, Rafter N, Horn E, Whittaker R, Stewart A, et al. Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice. Eur J Cardiovasc Prev Rehabil 2008; 15:173-8.